Suppr超能文献

通过实证分析和法律分析视角探讨数据利他主义在临床研究中的应用。

The application of data altruism in clinical research through empirical and legal analysis lenses.

作者信息

Lalova-Spinks Teodora, Meszaros Janos, Huys Isabelle

机构信息

Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Center for IT and IP Law (CiTiP), KU Leuven, Leuven, Belgium.

出版信息

Front Med (Lausanne). 2023 Mar 30;10:1141685. doi: 10.3389/fmed.2023.1141685. eCollection 2023.

Abstract

BACKGROUND

The legal framework for clinical research in the EU is complex and the lack of harmonization of the relevant legal and ethical rules remains one of the main challenges for stakeholders in the field. The recently adopted Data Governance Act (DGA) and the proposal for a European Health Data Space (EHDS) promise to solve the existing challenges with respect to access to and (re)use of personal data for research, but also risk to further complexify the field. The DGA introduced a novel mechanism - data altruism. Data altruism is understood as the voluntary sharing of personal and non-personal data, based on the consent of data subjects or the permission of natural and legal persons, without seeking a reward and for objectives of general interest. This study aimed to gain insights into the opinion of clinical research stakeholders on data altruism, and to critically discuss key issues pertaining to the application of data altruism from a legal point of view.

METHODS

Semi-structured interviews with (1) data protection officers (DPOs) and legal experts working with commercial and academic sponsors of clinical trials, (2) investigators, and (3) members of research ethics committees. Data underwent framework analysis. The legal discussion was comprised of legal doctrinal research with focus on the DGA, EHDS proposal, and the interplay with the EU General Data Protection Regulation (GDPR).

RESULTS

Fourteen experts took part in the interviews, more than half of which were DPOs/legal experts. Interviewees were based in seven EU Member states and the United Kingdom. The majority of participants were critical towards the data altruism mechanism and pointed out challenges and risks associated with its application.

CONCLUSION

Although data altruism holds the potential to facilitate data sharing, its application in clinical research at the moment is still riddled with uncertainties. The interplay of the DGA rules with the provisions of the GDPR and the EHDS proposal are insufficiently clear and further efforts from the legislator are required to build a working, patient-centered, and research fostering data altruism system.

摘要

背景

欧盟临床研究的法律框架复杂,相关法律和伦理规则缺乏协调统一仍是该领域利益相关者面临的主要挑战之一。最近通过的《数据治理法案》(DGA)和欧洲健康数据空间(EHDS)提案有望解决在研究中获取和(再)利用个人数据方面的现有挑战,但也有使该领域进一步复杂化的风险。DGA引入了一种新机制——数据利他主义。数据利他主义被理解为基于数据主体的同意或自然人和法人的许可,自愿分享个人和非个人数据,不寻求回报且出于普遍利益目的。本研究旨在深入了解临床研究利益相关者对数据利他主义的看法,并从法律角度批判性地讨论与数据利他主义应用相关的关键问题。

方法

对(1)与临床试验商业和学术赞助商合作的数据保护官(DPO)和法律专家、(2)研究人员以及(3)研究伦理委员会成员进行半结构化访谈。数据进行框架分析。法律讨论包括以DGA、EHDS提案以及与欧盟《通用数据保护条例》(GDPR)的相互作用为重点的法律教义研究。

结果

14名专家参与了访谈,其中一半以上是DPO/法律专家。受访者来自7个欧盟成员国和英国。大多数参与者对数据利他主义机制持批评态度,并指出了其应用相关的挑战和风险。

结论

尽管数据利他主义有促进数据共享的潜力,但其目前在临床研究中的应用仍充满不确定性。DGA规则与GDPR条款以及EHDS提案之间的相互作用不够清晰,立法者需要进一步努力构建一个可行的、以患者为中心且促进研究的数据利他主义体系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f54c/10098212/0b497e752342/fmed-10-1141685-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验